References
- Smith RK, Carroll PM, Allard JD and Simon MA (2002) MASK, a large ankyrin repeat and KH domain-containing protein involved in Drosophila receptor tyrosine kinase signaling. Development 129, 71-82 https://doi.org/10.1242/dev.129.1.71
- Li J, Mahajan A and Tsai MD (2006) Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 45, 15168-15178 https://doi.org/10.1021/bi062188q
- Islam Z, Nagampalli RSK, Fatima MT and Ashraf GM (2018) New paradigm in ankyrin repeats: Beyond proteinprotein interaction module. Int J Biol Macromol 109, 1164-1173 https://doi.org/10.1016/j.ijbiomac.2017.11.101
- Sedgwick SG and Smerdon SJ (1999) The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci 24, 311-316 https://doi.org/10.1016/S0968-0004(99)01426-7
- Mosavi LK, Cammett TJ, Desrosiers DC and Peng ZY (2004) The ankyrin repeat as molecular architecture for protein recognition. Protein Sci 13, 1435-1448 https://doi.org/10.1110/ps.03554604
- Hollenbeck JJ, Danner DJ, Landgren RM, Rainbolt TK and Roberts DS (2012) Designed ankyrin repeat proteins as scaffolds for multivalent recognition. Biomacromolecules 13, 1996-2002 https://doi.org/10.1021/bm300455f
- Valverde R, Edwards L and Regan L (2008) Structure and function of KH domains. FEBS J 275, 2712-2726 https://doi.org/10.1111/j.1742-4658.2008.06411.x
- Nazarov IB, Bakhmet EI and Tomilin AN (2019) KHDomain poly(C)-binding proteins as versatile regulators of multiple biological processes. Biochemistry (Mosc) 84, 205-219 https://doi.org/10.1134/s0006297919030039
- Nicastro G, Taylor IA and Ramos A (2015) KH-RNA interactions: back in the groove. Curr Opin Struct Biol 30, 63-70 https://doi.org/10.1016/j.sbi.2015.01.002
- Fragiadaki M and Zeidler MP (2018) Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs. J Biol Chem 293, 9570-9579 https://doi.org/10.1074/jbc.RA117.000975
- Yang C, Zheng J, Liu X et al (2020) Role of ANKHD1/LINC00346/ZNF655 feedback loop in regulating the glioma angiogenesis via staufen1-mediated mRNA decay. Mol Ther Nucleic Acids 20, 866-878 https://doi.org/10.1016/j.omtn.2020.05.004
- Sidor C, Borreguero-Munoz N, Fletcher GC, Elbediwy A, Guillermin O and Thompson BJ (2019) Mask family proteins ANKHD1 and ANKRD17 regulate YAP nuclear import and stability. Elife 8, e48601 https://doi.org/10.7554/eLife.48601
- Miles MC, Janket ML, Wheeler ED et al (2005) Molecular and functional characterization of a novel splice variant of ANKHD1 that lacks the KH domain and its role in cell survival and apoptosis. FEBS J 272, 4091-4102 https://doi.org/10.1111/j.1742-4658.2005.04821.x
- Santos Duarte Ada S, Traina F, Favaro PM et al (2005) Characterisation of a new splice variant of MASK-BP3(ARF) and MASK human genes, and their expression patterns during haematopoietic cell differentiation. Gene 363, 113-122 https://doi.org/10.1016/j.gene.2005.08.002
- Traina F, Favaro PM, Medina Sde S et al (2006) ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. Biochim Biophys Acta 1762, 828-834 https://doi.org/10.1016/j.bbadis.2006.07.010
- Muller P, Kuttenkeuler D, Gesellchen V, Zeidler MP and Boutros M (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature 436, 871-875 https://doi.org/10.1038/nature03869
- Fisher KH, Fragiadaki M, Pugazhendhi D et al (2018) A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability. J Cell Sci 131, jcs209551 https://doi.org/10.1242/jcs.209551
- Patera F, Hautbergue GM, Wilson P, Evans PC, Ong AC and Fragiadaki M (2020) Ankhd1 enhances polycystic kidney disease development via promoting proliferation and fibrosis, bioRxiv (https://doi.org/10.1101/2020.03.04.977017)
- Sidor CM, Brain R and Thompson BJ (2013) Mask proteins are cofactors of Yorkie/YAP in the Hippo pathway. Curr Biol 23, 223-228 https://doi.org/10.1016/j.cub.2012.11.061
- Sansores-Garcia L, Atkins M, Moya IM et al (2013) Mask is required for the activity of the Hippo pathway effector Yki/YAP. Curr Biol 23, 229-235 https://doi.org/10.1016/j.cub.2012.12.033
- Du Toit A (2013) Cell signalling: A new Hippo pathway component. Nat Rev Mol Cell Biol 14, 196 https://doi.org/10.1038/nrm3534
- Yu FX, Zhao B and Guan KL (2015) Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811-828 https://doi.org/10.1016/j.cell.2015.10.044
- Machado-Neto JA, Lazarini M, Favaro P et al (2014) ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res 324, 137-145 https://doi.org/10.1016/j.yexcr.2014.04.004
- Yao P, Li Y, Shen W et al (2018) ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT. Am J Cancer Res 8, 2311-2324
- Liu X-F, Han Q, Rong X-Z et al (2020) ANKHD1 promotes proliferation and invasion of non-small-cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway. Int J Oncol 56, 1175-1185
- Machado-Neto JA, Lazarini M, Favaro P et al (2015) ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. Biochim Biophys Acta 1853, 583-593 https://doi.org/10.1016/j.bbamcr.2014.12.012
- Machado-Neto JA, de Melo Campos P, Favaro P et al (2014) Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leuk Res 38, 251-257 https://doi.org/10.1016/j.leukres.2013.11.013
- Machado-Neto JA, Saad ST and Traina F (2014) Stathmin 1 in normal and malignant hematopoiesis. BMB Rep 47, 660-665 https://doi.org/10.5483/BMBRep.2014.47.12.020
- Dhyani A, Duarte AS, Machado-Neto JA, Favaro P, Ortega MM and Olalla Saad ST (2012) ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. FEBS Lett 586, 4311-4318 https://doi.org/10.1016/j.febslet.2012.10.037
- Dhyani A, Machado-Neto JA, Favaro P and Saad ST (2015) ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth. Eur J Cancer 51, 252-259 https://doi.org/10.1016/j.ejca.2014.11.012
- Dhyani A, Favaro P and Saad STO (2020) ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells. Blood Cells Mol Dis 84, 102460 https://doi.org/10.1016/j.bcmd.2020.102460
- Zhou Z, Jiang H, Tu K et al (2019) ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 38, 18 https://doi.org/10.1186/s13046-018-1011-0
- Zhu M, Li X, Tian X and Wu C (2015) Mask loss-offunction rescues mitochondrial impairment and muscle degeneration of Drosophila pink1 and parkin mutants. Hum Mol Genet 24, 3272-3285 https://doi.org/10.1093/hmg/ddv081
- Kitamata M, Hanawa-Suetsugu K, Maruyama K and Suetsugu S (2019) Membrane-deformation ability of ANKHD1 is involved in the early endosome enlargement. iScience 17, 101-118 https://doi.org/10.1016/j.isci.2019.06.020
- Hou SC, Chan LW, Chou YC et al (2009) Ankrd17, an ubiquitously expressed ankyrin factor, is essential for the vascular integrity during embryogenesis. FEBS Lett 583, 2765-2771 https://doi.org/10.1016/j.febslet.2009.07.025